-
ATENOLOL (Ternormin)
- Classification
- Beta blockers
- Antianginals
- Antihypertensives
- Indication
- Management of HTN
- Management of angina pectoris
- Prevention of MI
- Effects
- Decrease BP and HR
- Decrease frequency of attacks of angina pectoris
- Prevention of MI
-
METOPROLOL (Lopressor)
- Classification
- Beta blockers
- Antianginals
- Antihypertensives
- Indication
- HTN
- Angina pectoris
- Prevention of MI and decreased mortality in pt w/
- recent MI
- Management of stable, symptomatic HF d/t ischemic,
- hypertensive or cardiomyopathic origin
- Effects
- Decrease BP and HR
- Decrease frequency of attacks of angina pectoris
- Decrease rate of cardiovascular mortality and
- hospitalization in pt w/ HF
-
CARVEDILOL (Coreg)
- Classification
- Beta blockers
- Antihypertensives
- Indication
- HTN
- CHF (ischemic or cardiomyopathic) w/ digoxin,
- diuretics, and ACE inhibitors
- Left ventricular dysfunction after myocardial infarction
- Effects
- Decrease HR and BP
- Improve cardiac output, slowing of the progression of
- CHF and decreased risk of death
-
LABETALOL (Trandate)
- Classification
- Beta blockers
- Antianginals
- Antihypertensives
- Indication
- Management of HTN
-
PROPANOLOL (Inderal)
- Classification
- Beta blocker
- Antianginal
- Antiarrhythmics
- Antihypertensives
- Vascular headache suppressants
- Indication
- Management of HTN, angina, arrythmias,
- hypertrophic cardiomyopathy, thyotoxicosis, essential
- tremors, pheochromocytoma
- Also used in the prevention of MI, and of vascular
- headaches
- Effects
- Decrease HR and BP
- Suppression of arrhythmias
- Prevention of MI
-
CAPTOPRIL (Capoten)
- Classification
- Ace inhibitor
- Antihypertensives
- Indication
- Alone or w/ other agents in the management of HTN
- Management of HF
- Reduction of risk of death, HF-related hospitalizations,
- and development of overt HF following MI
- RX of diabetic nephropathy in pt w/ type 1 DM and
- retinopathy
- Effects
- Lowering of BP in pt w/ HTN
- Improve survival and reduced sx in pt w/ HF
- Improve survival and reduced development of overt
- HF after MI
- Decrease progression of diabetic nephropathy w/
- decrease need for transplantation of dialysis
-
ENALAPRIL (Vasotec)
- Classification
- Ace inhibitors
- Antihypertensives
- Indication
- Alone or w/ other agents in the management of HTN
- Management of symptomatic HF
- Slowed progression of asymptomatic left ventricular
- dysfunction to overt HF
- Effects
- Lowering of BP in pt w/ HTN
- Increase survival and reduction of sx in pt w/
- symptomatic HF
- Decreased development of overt HF
-
LISINOPRIL (Prinivil, Zastril)
- Classification
- Ace inhibitors
- Antihypertensives
- Indication
- Alone or w/ other agents in the management of HTN
- Management of HF
- Reduction of risk of death or development of HF after
- MI
- Effects
- Lowering of BP in pt w/ HTN
- Increase survival and decrease sx in pt w/ HF
- Increased survival after MI
-
DILTIAZEM (Cardizem)
- Classification
- Calcium channel blockers
- Antianginals
- Antiarrhythmics
- Antihypertensives
- Indication
- HTN
- Angina Pectoris and vasospastic (Prinsmetal's) angina
- Supraventricular tachyarrhythmias and rapid
- ventricular rates in A flutter or fib
- Effects
- Systemic vasodilation resulting in decrease BP
- Coronary vasodilation resulting in decreased frequency
- and severity of attacks of angina
- Reduction of ventricular rate in A flutter or fib
-
NIFEDIPINE (Procardia)
- Classification
- Calcium channel blockers
- Antianginals
- Antihypertensives
- Indication
- Management of HTN (extended release only)
- Management of angina pectoris
- Management of vasospastic (Prinsmetal's) angina
- Effects
- Systemic vasodilation, resulting in decrease BP
- Coronary vasodilation, resulting in decrease frequency
- and severity of attacks of angina
-
VERAPAMIL (Isoptin, Calan)
- Classification
- Calcium channel blockers
- Antianginals
- Antiarrhythmics
- Antihypertensives
- Vascular headache suppresants
- Indication
- Management of HTN, angina pectoris, and/ or
- vasospastic (Prinzmetal's) angina
- Management of supraventricular arrhythmias and repid
- ventricular rates in a flutter or fib
- Effects
- Systemic vasodilation resulting in decrease BP
- Coronary vasodilation resulting in decreased frequency
- and severity of attacks of angina
- Reduction of ventricular rate during a fib or flutter
-
LOVASTATIN (Mevacor)
- Classification
- Lipid-lowering agent
- HMG COA reductase inhibitors (statin)
- Indication
- Adjunctive management of primary
- hypercholesterolemia and mixed dyslipidemias
- Primary prevention of coronary heart disease (MI,
- unstable angina, and coronary revascularization) in
- asymptomatic pts w/ increased total and low- density
- lipoprotein (LDL) cholesterol and decreased high-
- density lipiprotein (HDL) cholesterol
- Slows the progression of coronary atherosclerosis in
- pts w/ coronary artery dz
- Effects
- Lowering of total and LDL cholesterol and
- triglycerides. Slighty increases HDL cholersterol
- Slows the progression of coronary atherosclerosis w/
- resultant decrease in coronary heart disease- related
- events
-
ATORVASTATIN (Lipitor)
- Classification
- Lipid-lowering agent
- HMG COA reductase inhibitors (statin)
- Indication
- Adjunctive management of primary
- hypercholesterolemia and mixed dyslipidemias
- Primary prevention of coronary heart disease (MI,
- unstable angina, and coronary revascularization) in
- asymptomatic pts w/ increased total and low- density
- lipoprotein (LDL) cholesterol and decreased high-
- density lipiprotein (HDL) cholesterol
- Effects
- Lowering of total and LDL cholesterol and
- triglycerides. Slighty increases HDL cholersterol
- Reduction of lipids/ cholesterol reduces the risk of MI
- and stroke sequelae
- Slows the progression of coronary atherosclerosis w/
- resultant decrease in coronary heart disease- related
- events
-
SIMVASTATIN (Zocor)
- Classification
- Lipid-lowering agents
- HMG COA reductase inhibitor (statin
- Indication
- Adjunctive management of primary
- hypercholesterolemia and mixed dyslipidemias
- Secondary prevention of myocardial infarction,
- coronary revascularization, stroke, and cardiovascular
- mortality in pts w/ clinically evident coronary heart dz
- Effects
- Lowering of total and LDL cholesterol and
- triglycerides. Slightly increases HDL cholesterol
- Slows the progression of coronary atherosclerosis w/
- resultant decrease in coronary heart disease-related
- events
-
NIACIN
- Classification
- Lipid-lowering agents
- Water soluble vitamins
- Indication
- Treatment and prevention of niacin deficiency
- (Pellagra)
- Adjunctive therapy in certain hyperlipidemias (niacin
- only)
- Effects
- Decrease blood lipids (niacin only)
- Supplementation in dificiency states
-
ALDACTONE (Spironolactone)
- Classification
- Diuretics
- Potassium-sparing diuretic
- Indication
- Management of primary hyperaldosteronism
- Management of edema associated w/ CHF, cirrhosis
- and nephrotic syndrome
- Management of essential hypertension
- Treatment of hypokalemia (counteracts potassium loss
- caused by other diuretics
- Effects
- Increase survival in pt w/ severe HF
- Weak diuretic and antihypertensive response when
- compared w/ other diuretics
- Conservation of potassium
-
LASIX (Furosemide)
- Classification
- Diuretics
- Loop diuretics
- Indication
- Edema d/t HF, hepatic impairment, or renal disease
- HTN
- Effect
- Diuresis and subsequent mobilization of excess fluid
- (edema, pleural effusions)
- Decrease BP
-
ISOSORBIDE
- Classification
- Antianginals
- Nitrates
- Indication
- Acute treatment of anginal attacks
- Prophylactic management of angina pectoris
- Treatment of chronic CHF
- Effect
- Produce vasodilation
- Relief and prevention of anginal attacks
-
COLACE (DOCUSATE)
- Classification
- Laxative
- Stool softener
- Indication
- PO: Prevention of constipation (in pt who should
- avoid straining, such as after MI or rectal surgery
- RECT: Used as enema to soften fecal impaction
- Effect
- Softening and passage of stool
-
SENOKOT (Sennosides)
- Classification
- Laxative
- Stimulant laxative
- Indication
- Treatment of constipation, particularly when associated
- w/:
- Slow transit time
- Constipating drugs
- Irritable or spastic bowel syndrome
- Neurologic constipation
-
ACETOMINOPHEN (Tylenol)
- Classification
- Antipyretics
- Nonopioid analgesics
- Indication
- Mild pain
- Fever
- Effect
- Has no significant anti-inflammatory properties or GI
- toxicity
- Analgesia
- Antipyresis
-
MORPHINE
- Classification
- Opioid analgesics/ agonists
- Indication
- Severe pain
- Pulmonary edema
- Pain associated with MI
- Effect
- Decrease in severity of pain
-
OXYCODONE (Oxycontin)
- Classification
- Opioid analgesics/ agonists
- Indication
- Moderate to severe pain
-
FENTANYL
- Classification
- Opioid analgesics/ agonists
- Oral transmucosal
- Indication
- Management of breakthrough cancer pain in pts w/
- malignancies who are already recieving and are
- tolerant to opioid therapy for their underlying
- cancer pain
- Parenteral
- Indication
- Analgesic supplement to general anesthesia; usually
- w/ other agents to produce balanced anesthesia
- Effect
- Supplement in anesthesia
- Decrease pain
- Sublingual
- Indication
- Management of breakthrough pain in opioid-
- tolerant cancer pts >= 18 yr who already recieve
- opioids for persistent cancer-related pain
- Effect
- Decrease breakthrough pain during chronic opioid
- therapy
- Transdermal
- Indication
- Moderate to severe chronic pain requiring
- continuous opioid analgesic therapy for an
- extended time at a dose of 25 mcg/hr or more of the
- transdermal system.
- Transdermal fentanyl is not recommended for the
- control of postoperative, mild, or intermittent pain,
- nor should it be used for short-term pain relief.
- Effect
- Decrease in severity of chonic pain
-
METHADONE
- Classification
- Opioid analgesics/ agonists
- Indication
- Severe pain
- Suppresses withdrawal symptoms in opioid
- detoxification
- Neonatal abstinence syndrome
- Effect
- Decrease in severity of pain
- Suppression of withdrawal symptoms during
- detoxification and maintenance from heroin and other
- opioids
-
DEMEROL (Meperidine)
- Classification
- Opioid analgesic/ agonist
- Indication
- Moderate or severe pain (alone or w/ nonopioid
- agents)
- Anesthesia adjunct
- Analgesic during labor
- Preoperative sedation
- Effect
- Decrease in severity of pain
-
DILAUDID (Hydromorphone)
- Classification
- Opioid agonists/ analgesic
- Allergy, cold and cough remedies (antitussive)
- Indication
- Moderate to severe pain (alone and in combo w/
- nonopioid analgesics); extended release product for
- opioid-tolerant pts requiring around-the-clock
- management of persistent pain
- Antitussive (lower doses)
- Effect
- Deacrease in moderate to severe pain
- Suppression of cough
-
NORCO (Hydrocodone)
- Classification
- Opioid agonist/ analgesic
- Allergy, cold and cough remedies (antitussive)
- Indication
- Used mainly in combo w/ nonopioid analgesics
- (acetaminophen/ ibuprofen) in the management of
- moderate to severe pain
- Antitussive (usually in combo products w/
- decongestants)
- Effect
- Decrease in severity of moderate pain
- Suppression of the cough reflex
-
VICODIN (Hydrocodone + Acetaminophen)
- Classification
- Opioid agonist/ analgesic
- Allergy, cold and cough remedies (antitussive)
- Indication
- Used mainly in combo w/ nonopioid analgesics
- (acetaminophen/ ibuprofen) in the management of
- moderate to severe pain
- Antitussive (usually in combo products w/
- decongestants)
- Effect
- Decrease in severity of moderate pain
- Suppression of the cough reflex
-
PERCOCET (Oxycodone Combunox)
- Classification
- Opioid analgesic/ agonist
- Indication
- Moderate to severe pain
-
BUTORPHANOL (Stadol)
- Classification
- Opioid analgesic/ agonist antogonist
- Indication
- Management of moderate to severe pain
- Analgesia during labor
- Sedation before surgery
- supplement in balanced anesthesia
- Effect
- Decrease severity of pain
-
NALBUPHINE (Nubain)
- Classification
- Opioid analgesic/ agonist
- Indication
- Moderate to severe pain
- Analgesia during labor
- Sedation before surgery
- Supplement to balanced anesthesia
-
IBUPROFIN (Advil, Motrin)
- Classification
- Nonsteroidal anti-inflammatory agents
- Antipyretics
- Antirheumatics
- Nonopioid analgesic
- Indication
- Mild to moderate pain or dysmenorrhea
- Inflammatory disorders including:
- Rheumatoid arthritis (including juvenile)
- Osteoarthritis
- Lowering of fevere
- Effect
- Decrease pain and inflammation
- Reduction of fever
-
ASPIRIN
- Classification
- Antipyretics
- Nonopioid analgesic
- Salicylate
- Indication
- Inflammatory disorders including:
- Rheumatoid arthritis
- Osteoarthritis
- Mild to moderate pain
- Fever
- Prophylaxis of transient ischemic atttacks and MI
- Effect
- Analgesia
- Reduction of inflammation
- Reduction of fever
- Decrease incidence of transient ischemic attacks and
- MI
-
KETOROLAC (Toradol)
- Classification
- Nonsteroidal anti-inflammatory agents
- Nonopioid analgesic
- Pyrroziline carboxylic acid
- Indication
- Short term management of pain (not to exceed 5 days
- total for all routes combined)
-
INDOMETHACIN (Indocin)
- Classification
- Antirheumatics
- Ductus arteriosus pateny adjuncts (IV only)
- Nonsteroidal anti-inflammatory agent
- Indication
- PO
- Inflammatory disorders including:
- Rheumation arthritis
- Gouty arthritis
- Osteoarthritis
- Ankylosing spondylitis
- Generally reserved for pt who do not respond to
- less toxic agents
- IV
- Alternative to surgery in the management of paten
- ductus arteriosus (PDA) in premature neonates
- Effect
- PO
- Suppression of pain and inflammation
- IV
- Closure of PDA
-
AMOXICILLIN
- Classification
- Anti-infectives
- Antiulcer agents
- Aminopenicillins
- Indication
- Treatment of:
- Skin and skin structure infections
- Otitis media
- Sinusitis
- Respiratory infections
- Genitourinary infections
- Endocarditis prophylaxis
- Postexposure inhalational anthrax prophylaxis
- Management of ulcer disease due to H. Pylori
- Effect
- Bactericidal action; spectrum is broader than penicillin
- Binds to bacterial cell wall, causing cell death
-
ANCEF (Cefazolin)
- Classification
- Anti-infectives
- First generation cephalosporins
- Indication
- Treatment of the following infections d/t susceptible
- organisms:
- Skin and skin structure infections (including burn
- wounds)
- Pneumonia
- UTI
- Biliary tract infections
- Genital infections
- Bone and joint infections
- Septicemia
- Bacterial endocarditis prophylaxis for dental and
- upper respiratory procedures
- Perioperative prophylaxis
- Not suitable for the treatment of meningitis
- Effect
- Bactericidal action against susceptible bacteria
|
|